Showing results (511-520 of 1,242) with videos related to
Sort By:
Pageof 125
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 15, 2016
Single and modeled multifrequency electrical impedance myography parameters and their relationship to force production in the ALS SOD1G93A mouseJia Li, Adam Pacheck, Benjamin Sanchez, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 26, 2017
Comparison of slow and forced vital capacities on ability to predict survival in ALSSusana Pinto, Mamede de CarvalhoAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 11, 2017
Lack of association between the P413L variant of chromogranin B and ALS risk or age at onset: a meta-analysisXinglong Yang, Shimei Li, Dongmei Xing, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
Edaravone and its clinical development for amyotrophic lateral sclerosisKoji Takei, Kazutoshi Watanabe, Satoshi Yuki, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
Introduction to supplement: the current status of treatment for ALSRobert G Miller, Stanley H AppelAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
What can we learn from the edaravone development program for ALS?Nicholas J MaragakisAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosisFumihiro Takahashi, Koji Takei, Kikumi Tsuda, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 6, 2017
Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation)Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 5, 2017
Ethics of clinical research in patients with ALS: is there a risk of exploitation?Carmel ArmonAmyotrophic Lateral Sclerosis & Frontotemporal Degeneration|October 30, 2015
Compliance with recommendations made in a multidisciplinary ALS clinicTimothy Fullam, Helen E Stephens, Stephanie H Felgoise, et al.Pageof 125